Neuromuscular Diseases
A general term encompassing lower MOTOR NEURON DISEASE; PERIPHERAL NERVOUS SYSTEM DISEASES; and certain MUSCULAR DISEASES. Manifestations include MUSCLE WEAKNESS; FASCICULATION; muscle ATROPHY; SPASM; MYOKYMIA; MUSCLE HYPERTONIA, myalgias, and MUSCLE HYPOTONIA.
Subtype terms (8)
More specific conditions that are subtypes of Neuromuscular Diseases in the MeSH hierarchy.
- Fatigue Syndrome, Chronic
76 drugs (43 approved, 33 experimental)
- Locked-In Syndrome
- Motor Neuron Disease
27 drugs (17 approved, 10 experimental)
- Muscular Diseases
29 drugs (20 approved, 9 experimental)
- Neuromuscular Junction Diseases
2 drugs approved
- Peripheral Nervous System Diseases
101 drugs (63 approved, 38 experimental)
- Poliomyelitis
55 drugs (32 approved, 23 experimental)
- Stiff-Person Syndrome
18 drugs (15 approved, 3 experimental)
Drugs by status
Phase 3 trials (6)
Phase 2 trials (11)
Phase 1 trials (3)
Organizations
Organization Involved with Phase 3 Indications (2)
Organization Involved with Phase 2 Indications (14)
- Amylyx Pharmaceuticals Inc.
- Penwest Pharmaceuticals Co.
- Capricor Inc.
- National Institute of Nursing Research (NINR)
- Harvard University
- Johns Hopkins University
- Newcastle University
- University of California, Davis
- Isfahan University
- ALS Association
- ALS Finding a Cure Foundation
- Northeast ALS Consortium
- Leandro P. Rizzuto Foundation
- Scholar Rock, Inc.
Organization Involved with Phase 1 Indications (2)
Organization Involved with Other Experimental Indications (3)